Benzinga's Top Pre-Market Losers

Amicus Therapeutics

shares dropped 46.97% to $3.06 in pre-market trading. Amicus Therapeutics and GlaxoSmithKline plc

today announced the 6-month primary treatment period results from the first Phase 3 global registration study. Allscripts Healthcare Solutions

shares fell 16.48% to $8.92 in the pre-market trading. Allscripts appointed Paul Black as its CEO. Accenture plc

dipped 5.21% to $66.73 in the pre-market session. Accenture projects Q2 revenue of $6.9 billion of $7.15 billion, versus analysts' estimates of $7.14 billion. Bed Bath & Beyond

dipped 4.86% to $57.35 in the pre-market session. Bed Bath & Beyond issued downbeat fourth-quarter earnings forecast. The company's board also authorized a new $2.5 billion share repurchase program.